Cargando…

PB1913: SYNERGISTIC EFFECTS OF DECITABINE AND APR-246 IN TP53 P.248Q-MUTATED MYELODYSPLASTIC SYNDROME

Detalles Bibliográficos
Autores principales:	Fang, Y., Chang, C.-K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431405/ http://dx.doi.org/10.1097/01.HS9.0000850504.79008.eb

Ejemplares similares

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
por: Maslah, Nabih, et al.
Publicado: (2020)

PB2154: TP53 GENE MUTATION DIVERSITY IN RUSSIAN PATIENTS WITH B-CELL LYMPHOMAS
por: Biderman, B., et al.
Publicado: (2022)

PB1912: MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND ASSOCIATED 5Q DELETION TO 13Q DELETION
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
por: Zeidan, Amer M., et al.
Publicado: (2023)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
por: Daver, N., et al.
Publicado: (2022)

PB1909: LOW-BURDEN TP53 MUTATIONS REPRESENT FREQUENT GENETIC EVENTS IN CLL WITH AN INCREASED RISK FOR TREATMENT INITIATION
por: László, Tamás, et al.
Publicado: (2023)

PB1997: TRISOMY 18 IN MYELODYSPLASTIC SYNDROMES
por: Abdelmoula, Nouha Bouayed, et al.
Publicado: (2023)

PB1916: SOMATIC MUTATIONS ASSOCIATED WITH MYELODYSPLASTIC SYNDROME IN RUSSIAN PATIENTS
por: Kohno, A., et al.
Publicado: (2022)

PB2385: CINOBUFAGIN PROMOTES APOPTOSIS OF DIFFUSE LARGE B LYMPHOMA CELLS BY INHIBITING UBIQUITINATION DEGRADATION OF TP53
por: He, Sanxiu, et al.
Publicado: (2023)

PB2169: LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE COMBINATION THERAPY IN CONCOMITANT MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND MULTIPLE MYELOMA
por: Koh, Yu Han, et al.
Publicado: (2023)

PB2013: THE FREQUENCY, EVOLUTION AND SIGNIFICANCE OF GENE MUTATION IN MYELODYSPLASTIC SYNDROMES WITH NORMAL KARYOTYPE
por: Xu, Feng, et al.
Publicado: (2023)

PB2358: PHASE 1-2 STUDY OF THE SAFETY, PK, PD, AND PRELIMINARY ACTIVITY OF TOLINAPANT IN COMBINATION WITH ORAL DECITABINE/CEDAZURIDINE AND ORAL DECITABINE/CEDAZURIDINE ALONE IN SUBJECTS WITH R/R PTCL
por: Shortt, Jake, et al.
Publicado: (2023)

PB2378: COMPREHENSIVE ANALYSIS OF P53-RESPONSIVE MIRNA’S GENES METHYLATION, TP53 GENE MUTATIONS AND POLYADENYLATION SIGNAL DESTRUCTION IN DIFFUSE LARGE B-CELL LYMPHOMA TUMOR TISSUE.
por: Voropaeva, Elena, et al.
Publicado: (2023)

PB2015: DIAGNOSIS, CLASSIFICATION AND STRATIFICATION OF MYELODYSPLASTIC SYNDROMES IN ALGERIA
por: Moussa, Yamina Bouchakour, et al.
Publicado: (2023)

PB2020: OUTCOMES OF PATIENTS WITH HIGH RISK MYELODYSPLASTIC SYNDROMES
por: Amor, Imen Ben, et al.
Publicado: (2023)

PB2025: CULTURAL DATA TO NEW CLASSIFICATION OF MYELODYSPLASTIC NEOPLASIA
por: Saralidze, Tamar, et al.
Publicado: (2023)

PB1996: CYTOGENETIC FEATURES OF 164 MOROCCAN PATIENTS WITH MYELODYSPLASTIC SYNDROME
por: Aghoutane, Yossra, et al.
Publicado: (2023)

PB1992: PROTEOMIC ANALYSIS REVEALS AUTOPHAGY INHIBITION IN MYELODYSPLASTIC SYNDROMES
por: Tsekoura, Georgia, et al.
Publicado: (2023)

PB2046: SHORT-TERM EFFICACY OF DECITABINE IN COMBINATION WITH LOW-DOSE CHEMOTHERAPY IN THE TREATMENT OF JMML: A RETROSPECTIVE STUDY
por: Cai, Y., et al.
Publicado: (2022)

PB2026: ROLE OF MOLECULAR PROFILING IN MYELODYSPLASTIC SYNDROME IN REAL-WORLD - A NEW APPROACH IN MYELODYSPLASTIC SYNDROME’S RISK STRATIFICATION?
por: Silva, Duarte Pacheco, et al.
Publicado: (2023)

PB1914: CYTOGENETIC FINDINGS IN 18 CHILDREN WITH MYELODYSPLASTIC SYNDROMES BY KARYOTYPIC AND FISH ANALYSIS
por: Manola, K., et al.
Publicado: (2022)

PB2029: ACQUIRED ALPHA THALASSEMIA IN ASSOCIATION WITH MYELODYSPLASTIC SYNDROME- A CASE REPORT
por: Balasubramanian, Priyavadhana, et al.
Publicado: (2023)

PB2011: TRANSFUSION BURDEN IS AN IMPORTANT PROGNOSTIC FACTOR IN LOWER-RISK MYELODYSPLASTIC SYNDROME
por: Lee, Jungmin, et al.
Publicado: (2023)

PB1913: IGH 3’RR RECOMBINATION UNCOVERS A NON-GC IMPRINT AND C-MYC-DEPENDENT IGH REARRANGEMENT ACTIVITY IN UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA
por: Jamal, Israa Al, et al.
Publicado: (2023)

PB2022: ELTROMBOPAG IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A SINGLE-CENTER EXPERIENCE
por: Peña, Amaia Lopez, et al.
Publicado: (2023)

PB2001: PROGNOSTIC FACTORS IN MYELODYSPLASTIC SYNDROMES- A SWEDISH RETROSPECTIVE REAL-WORLD STUDY
por: Schain, Frida, et al.
Publicado: (2023)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
por: Abrams, Stephen L., et al.
Publicado: (2022)

PB2263: SUPPORTIVE CARE IN LOW-RISK MYELODYSPLASTIC SYNDROMES: ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS)
por: Cerchione, C., et al.
Publicado: (2022)

PB1923: PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH HYPOMETHYLATING AGENT USE IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES
por: Zeidan, A., et al.
Publicado: (2022)

PB2672: EXPLORING UNMET NEEDS OF PATIENTS WITH MYELODYSPLASTIC NEOPLASMS AND CAREGIVERS IN A NATIONAL ITALIAN SURVEY
por: Crisà, Elena, et al.
Publicado: (2023)

PB2012: DESCRIBING TREATMENT PATTERNS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ACCORDING TO IPSS-R RISK CATEGORY
por: Corry, Sorcha, et al.
Publicado: (2023)

PB2027: EFFICACY OF THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROME WITH UNFAVORABLE IMMUNOPHENOTYPIC AND CYTOGENETIC PROGNOSIS.
por: Trubkina, Hanna, et al.
Publicado: (2023)

PB1849: EARLY SALVAGE THERAPY WITH VENETOCLAX AND 10-DAY DECITABINE IS FEASIBLE AND SAFE IN REFRACTORY AML: RESULTS FROM 11 PATIENTS WITH EARLY INDUCTION FAILURE
por: Borst, Carla, et al.
Publicado: (2023)

PB1924: ARE WE TAKING ADVANTAGE OF THERAPEUTIC OPTIONS IN MYELODYSPLASTIC SYNDROME?-REAL WORLD DATA FROM HUNGARY
por: Miltényi, Z., et al.
Publicado: (2022)

PB2206: FULL SPECTRAL FLOW CYTOMETRY ANALYSIS OF THE BONE MARROW IMMUNE MICROENVIRONMENT IN PATIENTS WITH MYELODYSPLASTIC SYNDROME
por: chen, M., et al.
Publicado: (2022)

PB1917: PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF ELEMENTS OF THE ADAPTIVE IMMUNITY IN THE MICROENVIRONMENT OF MYELODYSPLASTIC SYNDROMES TREATED WITH 5-AZACITIDINE
por: Tsakiraki, Z., et al.
Publicado: (2022)

PB2007: INTEGRATION OF TELEHEALTH IN DAILY CLINICAL PRACTICE IN PATIENTS WITH MYELODYSPLASTIC NEOPLASMS - STATUS QUO AND FUTURE PERSPECTIVES
por: Stauder, Reinhard, et al.
Publicado: (2023)

PB2017: CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023)

PB2670: EQOL-MDS TRIAL: PATIENT-REPORTED OUTCOMES IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA.
por: Oliva, Esther, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rmeoco3rc93b8ngj92aqgtnvhr